ASTRO Annual Meeting

ORLANDO, Fla. — Damian Green, MD, assistant professor at Seattle Cancer Care Alliance and University of Washington, offers insights into key myeloma-related studies presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — Interim PET scans served as a biomarker for relapse in patients with non-bulky, stage I to stage II Hodgkin’s lymphoma who received ABVD chemotherapy, according to initial study findings presented at the ASH Annual Meeting and Exposition.

Patients with severe hemophilia A who took Eloctate prophylactically experienced reduced annualized bleeding rates overall and in target joints, according to an abstract presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — The addition of eltrombopag to immunosuppressive treatment increased complete hematologic response rates in patients with treatment-naive severe aplastic anemia, according to results of a late-breaking abstract presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — The addition of idelalisib to bendamustine and rituximab prolonged PFS and OS among patients with relapsed/refractory chronic lymphocytic leukemia, according to results of a late-breaking abstract presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — Brentuximab vedotin conferred 100% objective response rates when combined with dacarbazine or bendamustine for the first-line treatment of older patients with Hodgkin’s lymphoma, according to results of an interim analysis presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — PET scans performed following two cycles of the chemotherapeutic regimen BEACOPP can be safely used to guide subsequent treatment, according to results of an interim analysis of a phase 3 trial presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — A depression diagnosis prior to allogeneic hematopoietic stem cell transplantation appeared associated with a greater risk for acute graft-versus-host disease and mortality, according to results from a retrospective study presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — Treatment with ibrutinib prolonged PFS and led to a significantly higher overall response rate compared with temsirolimus in previously treated patients with mantle cell lymphoma, according to phase 3 study results presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — Hematopoietic stem cell transplantation from human leukocyte antigen-matched siblings was successful among more than 90% of patients with severe sickle cell disease, according to results of an international registry-based study presented at the ASH Annual Meeting and Exposition.